Company / Accounts Receivable
Enveric Biosciences, Inc. Accounts Receivable History
FY2017-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$7.9M
FY2019
5-year range
$7.9M / $8.8M
FY2017-FY2019
Trend
+0.0%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $9M to $8M over the past 2 years.
Based on SEC 10-K filings.
$8M in FY2019.
Declined from $9M to $8M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, accounts receivable increased 0.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $7.9M | +0.0% |
| FY2018 | $7.9M | -10.9% |
| FY2017 | $8.8M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026